Blood test to predict relapse after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study is testing a blood test called AlloHeme that may help doctors predict whether your blood cancer will come back after a stem cell transplant. Joining this study could help you and your doctor monitor your recovery more closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with acute myeloid leukemia or myelodysplastic syndrome (including chronic myelomonocytic leukemia) and are scheduled for or have recently had a donor stem cell transplant.
- You are planning to receive the transplant from a matched or partially matched donor (not an identical twin or cord blood).
- If you have active disease before the transplant, your doctor plans a bone marrow check about 30 days after transplant to confirm remission.
- Your transplant must not involve any T-cell depleting treatments (like certain drugs or graft processing).
- You are willing to provide blood samples and other study-related data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.